PFIZER INC — Director's Dealing 2020

Feb 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2020-02-26

Reporting Person: Dolsten Mikael (President R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-26	Common Stock	A	45566.0000	$0.0000	Acquired	345753.0000	Direct
2020-02-26	Common Stock	F	15478.0000	$34.7200	Disposed	330275.0000	Direct
2020-02-26	Common Stock	F	22314.0000	$34.7200	Disposed	307961.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-27	Stock Appreciation Rights	$34.1000	A	212961.0000	Acquired	2025-02-27	Common Stock (212961.0000)	Direct
2020-02-27	Stock Appreciation Rights	$34.1000	A	182461.0000	Acquired	2027-02-27	Common Stock (182461.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1688.0000	Indirect

Footnotes

F1: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon).

F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).

F4: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F5: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.